Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Danielle Beekman, PhD
Element Materials Technology/Jones Microbiology Institute
Poster(s):
(P-1060)
In vitro
Activity of Gepotidacin Tested Against Molecularly Characterized
Escherichia coli
Isolates Responsible for Urinary Tract Infections in the US (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1061)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1360) Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1363) Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1364) Cefiderocol Activity against
Pseudomonas aeruginosa
Clinical Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT